Adenosine Receptor A3 (ADORA3) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) – Pipeline Review, H2 2017’, provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Ophthalmology, Gastrointestinal, Immunology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Toxicology, Cardiovascular, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders and Respiratory under development targeting Adenosine Receptor A3 (ADORA3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Can-Fite BioPharma Ltd

Huons Global Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

Can-Fite BioPharma Ltd

Huons Global Co Ltd

Adenosine Receptor A3 (ADORA3) - Drug Profiles

ACN-1052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis

Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.

Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017

Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea

Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer

Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson

Jul 17, 2017: Can-Fite's Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting

Jun 08, 2017: Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis

Jun 05, 2017: Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH

Jun 01, 2017: New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

May 16, 2017: Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study

May 03, 2017: Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

Apr 25, 2017: Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board

Feb 28, 2017: New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

Feb 08, 2017: Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Can-Fite BioPharma Ltd, H2 2017

Pipeline by Huons Global Co Ltd, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports